Patients with bipolar II disorder benefit from single dose of psilocybin
The Brown University Psychopharmacology Update March 4, 2024 DOI: 10.1002/pu.31143 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Open-label nonrandomized trial Peer reviewed |
|---|---|
| Sample size | 15 |
| Population | Adults with bipolar II disorder |
| Intervention | Psilocybin |
| Dose | 25 mg |
| Duration | 12-week endpoint |
| Topics | Psilocybin |
| Keywords | Bipolar disorder Pharmacology Hallucinogen Cognition |
| Key findings | A single 25 mg dose of psilocybin improved depressive symptoms in all 15 participants, with 12 meeting response and remission criteria at 12 weeks. |
Abstract
A single 25‐mg dose of psilocybin resulted in improvement in depressive symptoms in all 15 participants in an open‐label nonrandomized trial enrolling adults with bipolar II disorder. Twelve of the 15 participants met response and remission criteria at the study's 12‐week endpoint.
Comparable studies
Other non-randomized and open-label trials on psilocybin, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Patients with moderate-to-severe, unipolar, treatment-resistant major depression | 2016 | Open-label feasibility trial | n = 12 |
| Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Patients with severe, unipolar, treatment-resistant major depression | 2017 | Open-label trial | n = 20 |
| Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction Psychiatrically healthy nicotine-dependent smokers | 2014 | Open-label pilot study | n = 15 |
| Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression Patients with treatment-resistant depression | 2018 | Clinical trial | n = 20 |
| Safety, Tolerability, and Efficacy of Psilocybin in 9 Patients With Obsessive-Compulsive Disorder Subjects with obsessive-compulsive disorder (OCD) | 2006 | Controlled clinical trial |